As of May 25
| -0.03 / -0.84%|
The 3 analysts offering 12-month price forecasts for ADMA Biologics Inc have a median target of 13.00, with a high estimate of 15.00 and a low estimate of 8.50. The median estimate represents a +268.27% increase from the last price of 3.53.
The current consensus among 4 polled investment analysts is to Buy stock in ADMA Biologics Inc. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.